ATE325791T1 - Hydroxypipecolate-hydroxamsäure-derivative als mmp inhibitoren - Google Patents

Hydroxypipecolate-hydroxamsäure-derivative als mmp inhibitoren

Info

Publication number: ATE325791T1
Authority: AT; Austria
Prior art keywords: hydroxypipecolate; acid derivatives; hydroxamic acid; mmp inhibitors; mmp
Prior art date: 1998-08-12

Application number

AT99933076T

Other languages

English (en)

Inventor

Kim Francis Mcclure

Mark Carl Noe

Michael Anthony Letavic

Louis Stanley Chupak

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-12

Filing date

1999-08-05

Publication date

2006-06-15

1999-08-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE325791T1 publication Critical patent/ATE325791T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Transplantation (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

AT99933076T 1998-08-12 1999-08-05 Hydroxypipecolate-hydroxamsäure-derivative als mmp inhibitoren ATE325791T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9623298P	1998-08-12	1998-08-12

Publications (1)

Publication Number	Publication Date
ATE325791T1 true ATE325791T1 (de)	2006-06-15

Family

ID=22256467

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99933076T ATE325791T1 (de)	1998-08-12	1999-08-05	Hydroxypipecolate-hydroxamsäure-derivative als mmp inhibitoren

Country Status (43)

Country	Link
US (2)	US6329397B1 (de)
EP (1)	EP1104403B1 (de)
JP (1)	JP2002522528A (de)
KR (1)	KR20010085374A (de)
CN (1)	CN1316995A (de)
AP (1)	AP2001002070A0 (de)
AR (1)	AR019241A1 (de)
AT (1)	ATE325791T1 (de)
AU (1)	AU766366B2 (de)
BG (1)	BG105323A (de)
BR (1)	BR9912909A (de)
CA (1)	CA2340202C (de)
CZ (1)	CZ2001484A3 (de)
DE (1)	DE69931266T2 (de)
DZ (1)	DZ2870A1 (de)
EA (1)	EA200100126A1 (de)
EE (1)	EE200100086A (de)
ES (1)	ES2263279T3 (de)
GE (1)	GEP20033117B (de)
GT (1)	GT199900131A (de)
HK (1)	HK1040242A1 (de)
HN (1)	HN1999000131A (de)
HR (1)	HRP20010098A2 (de)
HU (1)	HUP0103452A3 (de)
ID (1)	ID27840A (de)
IL (1)	IL141030A0 (de)
IS (1)	IS5813A (de)
MA (1)	MA26675A1 (de)
NO (1)	NO20010686L (de)
NZ (1)	NZ509296A (de)
OA (1)	OA11594A (de)
PA (1)	PA8479201A1 (de)
PE (1)	PE20000951A1 (de)
PL (1)	PL346041A1 (de)
SK (1)	SK1872001A3 (de)
SV (1)	SV1999000123A (de)
TN (1)	TNSN99156A1 (de)
TR (1)	TR200100474T2 (de)
UA (1)	UA59453C2 (de)
UY (1)	UY25993A1 (de)
WO (1)	WO2000009485A1 (de)
YU (1)	YU5201A (de)
ZA (1)	ZA200101042B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7354894B2 (en)	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en)	1998-08-18	2005-01-25	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
AU754719B2 (en) *	1998-08-31	2002-11-21	Merck & Co., Inc.	Method of treating neurodegenerative diseases
US6509337B1 (en) *	1998-09-17	2003-01-21	Pfizer Inc.	Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (de) *	1999-08-12	2001-03-07	Pfizer Products Inc.	Selektive Inhibitoren von Aggrecanase zur Behandlung von Osteoarthritis
EP1138680A1 (de) *	2000-03-29	2001-10-04	Pfizer Products Inc.	Gem substituierte Sulfonylhydroxamsäuren mit MMP inhibierender Wirkung
JP2001322977A (ja) *	2000-05-12	2001-11-20	Kotobuki Seiyaku Kk	ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) *	2000-09-27	2002-04-10	Shionogi & Co Ltd	新規マトリックスメタロプロテアーゼ阻害剤
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
CA2433772C (en)	2001-02-14	2008-10-07	Warner-Lambert Company Llc	Pyrimidine matrix metalloproteinase inhibitors
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
MXPA04002537A (es)	2001-10-12	2004-05-31	Warner Lambert Co	Alquinos como inhibidores de metaloproteinasa de matriz.
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
CA2494249A1 (en) *	2002-06-26	2004-01-08	Koichi Yokota	Novel azasugar derivative and drug containing the same as the active ingredient
JP2006502991A (ja) *	2002-07-17	2006-01-26	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリックスメタロプロテイナーゼ−１３のアロステリックアルキン阻害剤とセレコキシブまたはバルデコキシブではないシクロオキシゲナーゼ−２の選択的阻害剤との組合せ物
JP2006502114A (ja) *	2002-07-17	2006-01-19	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	マトリクスメタロプロテイナーゼ−１３のアロステリックアルキン阻害薬とセレコキシブまたはバルデコキシブとの組合せ
AU2003249540A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
WO2004014866A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
WO2004014923A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014909A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
MXPA05001603A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
MXPA05001783A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
AU2003250466A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014908A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Heterobicylcic metalloproteinase inhibitors
WO2004014880A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Chromone derivatives as matrix metalloproteinase inhibitors
BRPI0611550A2 (pt) *	2005-03-22	2009-01-13	Innodia Inc	uso de um composto selecionado do grupo que consiste em isâmeros de 4-hidràxi isoleucina, anÁlogos de 4-hidràxi isoleucina, e lactonas, sais, metabàlitos, solvatos e/ou prà-medicamentos farmaceuticamente aceitÁveis dos ditos isâmeros e anÁlogos, composto, kit farmacÊutico, composiÇço farmacÊutica, uso do composto e kit com composto
PT2105164E (pt)	2008-03-25	2011-03-24	Affectis Pharmaceuticals Ag	Novos antagonistas de p2x7r e a sua utilização
CN102395562A (zh)	2009-04-14	2012-03-28	阿费克蒂斯制药股份公司	新的p2x7r拮抗剂及其用途
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
DE202016007195U1 (de)	2016-11-16	2017-11-17	Bernhard Kohler	Strombegrenzende Schalteinrichtung
WO2020160140A1 (en) *	2019-01-29	2020-08-06	Darsha Llc	Compositions and methods for treating pulmonary disease with matrix metalloproteinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT821671E (pt) *	1995-04-20	2001-04-30	Pfizer	Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
GEP20012388B (en) *	1995-12-08	2001-03-25	Agouron Pharma	Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
JP3541043B2 (ja) *	1996-08-28	2004-07-07	ザプロクターアンドギャンブルカンパニー	置換環状アミンメタロプロテアーゼ阻害剤
ATE248812T1 (de) *	1997-02-03	2003-09-15	Pfizer Prod Inc	Arylsulfonylhydroxamsäurederivate
IL131123A0 (en) *	1997-02-11	2001-01-28	Pfizer	Arylsulfonyl hydroxamic acid derivatives
AU7294098A (en) *	1997-05-09	1998-11-27	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

1999
- 1999-05-08 UA UA2001010473A patent/UA59453C2/uk unknown
- 1999-07-30 PA PA19998479201A patent/PA8479201A1/es unknown
- 1999-08-03 YU YU5201A patent/YU5201A/sh unknown
- 1999-08-05 AP APAP/P/2001/002070A patent/AP2001002070A0/en unknown
- 1999-08-05 PL PL99346041A patent/PL346041A1/xx not_active Application Discontinuation
- 1999-08-05 KR KR1020017001847A patent/KR20010085374A/ko not_active Application Discontinuation
- 1999-08-05 CN CN99810697A patent/CN1316995A/zh active Pending
- 1999-08-05 EA EA200100126A patent/EA200100126A1/ru unknown
- 1999-08-05 IL IL14103099A patent/IL141030A0/xx unknown
- 1999-08-05 AU AU49247/99A patent/AU766366B2/en not_active Ceased
- 1999-08-05 EP EP99933076A patent/EP1104403B1/de not_active Expired - Lifetime
- 1999-08-05 TR TR2001/00474T patent/TR200100474T2/xx unknown
- 1999-08-05 EE EEP200100086A patent/EE200100086A/xx unknown
- 1999-08-05 NZ NZ509296A patent/NZ509296A/en unknown
- 1999-08-05 SK SK187-2001A patent/SK1872001A3/sk unknown
- 1999-08-05 GE GEAP19995744A patent/GEP20033117B/en unknown
- 1999-08-05 AT AT99933076T patent/ATE325791T1/de not_active IP Right Cessation
- 1999-08-05 BR BR9912909-4A patent/BR9912909A/pt not_active Application Discontinuation
- 1999-08-05 CZ CZ2001484A patent/CZ2001484A3/cs unknown
- 1999-08-05 ES ES99933076T patent/ES2263279T3/es not_active Expired - Lifetime
- 1999-08-05 ID IDW20010327A patent/ID27840A/id unknown
- 1999-08-05 JP JP2000564939A patent/JP2002522528A/ja not_active Ceased
- 1999-08-05 HU HU0103452A patent/HUP0103452A3/hu unknown
- 1999-08-05 CA CA002340202A patent/CA2340202C/en not_active Expired - Fee Related
- 1999-08-05 DE DE69931266T patent/DE69931266T2/de not_active Expired - Fee Related
- 1999-08-05 OA OA1200100035A patent/OA11594A/en unknown
- 1999-08-05 WO PCT/IB1999/001388 patent/WO2000009485A1/en active IP Right Grant
- 1999-08-09 HN HN1999000131A patent/HN1999000131A/es unknown
- 1999-08-10 PE PE1999000807A patent/PE20000951A1/es not_active Application Discontinuation
- 1999-08-10 AR ARP990103994A patent/AR019241A1/es not_active Application Discontinuation
- 1999-08-11 MA MA25730A patent/MA26675A1/fr unknown
- 1999-08-11 DZ DZ990170A patent/DZ2870A1/xx active
- 1999-08-11 SV SV1999000123A patent/SV1999000123A/es not_active Application Discontinuation
- 1999-08-11 TN TNTNSN99156A patent/TNSN99156A1/fr unknown
- 1999-08-12 GT GT199900131A patent/GT199900131A/es unknown
- 1999-08-12 US US09/372,946 patent/US6329397B1/en not_active Expired - Fee Related
2000
- 2000-01-28 UY UY25993A patent/UY25993A1/es unknown
2001
- 2001-01-16 IS IS5813A patent/IS5813A/is unknown
- 2001-02-07 ZA ZA200101042A patent/ZA200101042B/en unknown
- 2001-02-08 HR HR20010098A patent/HRP20010098A2/hr not_active Application Discontinuation
- 2001-02-09 NO NO20010686A patent/NO20010686L/no not_active Application Discontinuation
- 2001-03-09 BG BG105323A patent/BG105323A/xx unknown
- 2001-12-03 US US10/008,943 patent/US20030008901A1/en not_active Abandoned
2002
- 2002-02-26 HK HK02101437.7A patent/HK1040242A1/zh unknown

Also Published As

Publication number	Publication date
UY25993A1 (es)	2000-03-31
EA200100126A1 (ru)	2001-08-27
WO2000009485A1 (en)	2000-02-24
TNSN99156A1 (fr)	2005-11-10
AU4924799A (en)	2000-03-06
HN1999000131A (es)	2000-03-24
HUP0103452A3 (en)	2002-10-28
IL141030A0 (en)	2002-02-10
CA2340202C (en)	2006-02-07
HRP20010098A2 (en)	2002-02-28
KR20010085374A (ko)	2001-09-07
OA11594A (en)	2004-07-11
AR019241A1 (es)	2001-12-26
ZA200101042B (en)	2002-10-07
BR9912909A (pt)	2001-05-08
HK1040242A1 (zh)	2002-05-31
BG105323A (en)	2001-10-31
JP2002522528A (ja)	2002-07-23
MA26675A1 (fr)	2004-12-20
AP2001002070A0 (en)	2001-03-31
NZ509296A (en)	2003-10-31
HUP0103452A2 (hu)	2002-04-29
US6329397B1 (en)	2001-12-11
PE20000951A1 (es)	2000-09-27
DE69931266T2 (de)	2007-02-15
GEP20033117B (en)	2003-11-25
TR200100474T2 (tr)	2001-06-21
PA8479201A1 (es)	2000-09-29
GT199900131A (es)	2001-02-02
EE200100086A (et)	2002-08-15
CA2340202A1 (en)	2000-02-24
DE69931266D1 (en)	2006-06-14
EP1104403A1 (de)	2001-06-06
AU766366B2 (en)	2003-10-16
EP1104403B1 (de)	2006-05-10
CN1316995A (zh)	2001-10-10
SV1999000123A (es)	2000-07-06
ID27840A (id)	2001-04-26
SK1872001A3 (en)	2002-08-06
NO20010686D0 (no)	2001-02-09
NO20010686L (no)	2001-04-09
PL346041A1 (en)	2002-01-14
IS5813A (is)	2001-01-16
ES2263279T3 (es)	2006-12-01
YU5201A (sh)	2003-07-07
UA59453C2 (uk)	2003-09-15
CZ2001484A3 (cs)	2002-05-15
US20030008901A1 (en)	2003-01-09
DZ2870A1 (fr)	2003-12-15

Publication	Publication Date	Title
ATE325791T1 (de)	2006-06-15	Hydroxypipecolate-hydroxamsäure-derivative als mmp inhibitoren
ATE257151T1 (de)	2004-01-15	Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
ATE493406T1 (de)	2011-01-15	Hydantoinderivate als mmp-inhibitoren
DK1070069T3 (da)	2003-10-06	Bicycliske hydroxaminsyrederivater
ATE245142T1 (de)	2003-08-15	No-synthase inhibitoren
NO993836D0 (no)	1999-08-10	Arylsulfonyl-hydroksamsyre-derivater
NO993730L (no)	1999-10-01	Arylsulfonylamino-hydroksamsyrederivater
ATE376999T1 (de)	2007-11-15	Hydroxamate-derivate als deacetylase inhibitoren
DE60002193D1 (de)	2003-05-22	Metalloprotease inhibitoren
DK0821671T3 (da)	2001-04-23	Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
EE200100410A (et)	2002-12-16	Sulfamaathüdroksaamhappe metalloproteaasi inhibiitor
DE69906311D1 (de)	2003-04-30	Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
DE60043730D1 (de)	2010-03-11	Arylsulfonamid-substituierte hydroxamsäure-derivate
DE60008548D1 (de)	2004-04-01	Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren
NO20014243D0 (no)	2001-08-31	Dihetero-substituerte metalloprotease inhibitorer
DE60012303D1 (de)	2004-08-26	Alkinylische hydroxamsäureverbindungen als tace inhibitoren
DE60009260D1 (de)	2004-04-29	Thiopyranderivate as mmp-inhibitoren
AU2201701A (en)	2001-06-25	Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors
ATE323673T1 (de)	2006-05-15	Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren
ATE227288T1 (de)	2002-11-15	Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren
AU2001247399A1 (en)	2002-09-24	Heterocyclic hydroxamic acid derivatives as mmp inhibitors

Legal Events

Date	Code	Title	Description
2006-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties